Key Takeaway:
- Syngenta’s H1 2025 sales reached $14.5 billion, flat year-on-year, up 2% at constant exchange rates (CER).
- EBITDA rose 24% year-on-year to $2.5 billion (+29% at CER), with margin up to 17.5% from 14.1%.
- Q2 2025 sales held steady at $7.2 billion, with EBITDA up 32% year-on-year to $1.1 billion.
- Crop Protection and Seeds units posted growth, while Group China saw lower sales due to strategic exits.
- Company expects stable sales and margins in the second half of 2025.
Financial Highlights
Syngenta Group reported sales of $14.5 billion in the first half of 2025, maintaining the prior year’s level but showing a 2% increase at constant exchange rates (CER). EBITDA rose to $2.5 billion, up 24% year-on-year (+29% at CER). The EBITDA margin expanded to 17.5%, a 3.4 percentage point increase compared with H1 2024.
Second quarter sales were $7.2 billion, flat versus the prior year (+1% at CER). EBITDA for the quarter reached $1.1 billion, a 32% increase year-on-year (+34% at CER). Management highlighted disciplined cost control, productivity gains, and a global manufacturing network that helped offset currency impacts.
Business Segment Performance
- Syngenta Crop Protection: H1 sales were $6.4 billion, up 3% (+7% CER). Growth was driven by biologicals, new product introductions, and strong performance in China (+9% in H1) and North America (+10%). Latin America sales fell 14%, while Brazil declined 5%. Over 800 new product approvals were secured, including TYMIRIUM® technology in Brazil.
- Seeds: H1 sales rose 2% to $2.4 billion (+3% CER). Growth came from China (+14%) and Brazil (+10%), while North America was slightly lower. Vegetable Seeds rose 5%, Flowers declined 2%. Notable launches included hybrid rice in Vietnam and expanded biotech corn offerings in Asia.
- Syngenta Group China: Sales reached $4.9 billion, down 5% (-4% CER), largely due to continued exits from lower-margin grain trading. Seeds sales grew 15%, Crop Nutrition sales increased 6%, and Branded Formulation sales rose 6%.
- ADAMA: Sales remained steady at $2.1 billion (+1% CER). North America grew 19%, while Latin America (-9%) and Asia Pacific excluding China (-19%) declined. The “Fight Forward” transformation plan continues to improve profitability, with five consecutive quarters of EBITDA growth.
Syngenta’s Strategic Developments
The goup highlighted investments in biologicals, including the opening of a new 22,000 m² facility in Orangeburg, South Carolina, capable of producing 16,000 tons of biostimulants annually. Integration of Novartis’ Strains and Natural Products Collection is expected to accelerate bio-based R&D.
The Seeds business advanced a next-generation soybean herbicide tolerance trait stack, while in China, 12 new GM corn varieties were certified. The Group’s Modern Agriculture Platform (MAP) continues to expand with AI-driven tools such as “iMAP.”
Syngenta’s Outlook
With signs of crop protection market stabilization and a lower baseline from 2024, Syngenta expects stable sales and margins in the second half of 2025. Management reiterated that tariff changes and currency fluctuations are not expected to materially impact business performance this year.
Read the full financial report here.
6 Comments